Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001
Effect of He-O2 breathing and inhaled salbutamol on expiratory flow limitation and dynamic hyperinflation in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 197s Year: 2002
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD Source: Eur Respir J 2001; 17: 1132-1137 Year: 2001
Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma Source: Eur Respir J 2007; 29: 871-878 Year: 2007
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
Maintenance plus as-needed budesonide/formoterol vs salmeterol/fluticasone in a real-life setting Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
Improved lung function and symptom control with formoterol on demand in asthma Source: Eur Respir J 2006; 27: 504-510 Year: 2006
Evaluation of the response of airway obstruction to short-acting inhaled broncodilators with using FIV1 and FEV1 in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005
The effect of nebulised MgSO4 on lung function in stable severe asthma patients with persistent airflow limitation Source: Annual Congress 2007 - New drugs for asthma Year: 2007
Comparative effects of formoterol monotherapy versus formoterol plus tiotropium on dynamic hyperinflation and exercise tolerance in COPD Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009
Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Effects of inhaled formoterol on dynamic hyperinflation during and after incremental treadmill exercise in patients with advanced COPD Source: Eur Respir J 2006; 28: Suppl. 50, 172s Year: 2006
Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Normal lung function and absence of bronchodilator response in children with stable, controlled asthma using inhaled corticosteroids Source: Annual Congress 2006 - New features of paediatric asthma Year: 2006
Improvements in inspiratory capacity with tiotropium in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 491s Year: 2002
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Source: Eur Respir J 2002; 19: 865-871 Year: 2002